reference standard raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
Reviewed 2025-10-06. Anything still debated is marked as such rather than presented as settled.
Analytical methods for SR9009 typically rely on liquid chromatography coupled with tandem mass spectrometry. The technique can separate the parent compound from related substances and detect low concentrations in biological matrices. Urine and blood are common samples in anti-doping testing, while in vitro studies may use cell culture media. Rapid metabolism and low expected concentrations make method validation important for reliable identification. Exact metabolite patterns can vary by species and are not fully mapped.
Regulatory treatment of SR9009 reflects its investigational status. The compound has no approved human therapeutic indication, and sports authorities prohibit its use. It appears on anti-doping lists as a non-approved substance or metabolic modulator, depending on the list version. Products sold online as research chemicals are not quality-controlled medicines, so their identity and purity can differ from the label. Such products may also contain unlisted compounds, which complicates both testing and safety assessment.
Scientific discussion of SR9009 often separates animal evidence from human anecdote. Rodent studies provide controlled data on endurance, metabolism, and gene expression, but they use specific strains, doses, and treatment durations. Human reports are mostly uncontrolled and cannot establish cause and effect. Open questions include oral bioavailability, tissue distribution, metabolic stability, and long-term effects. Review articles generally call for more rigorous pharmacokinetic and safety research before any clinical use could be considered.
SR9009 is not approved as a medicine by major regulatory agencies. It is commonly sold as a research chemical, a category that may fall outside customary drug approval and quality rules. In sports, the World Anti-Doping Agency lists SR9009 as a prohibited substance. Athletes who use it can face sanctions if it is detected in a sample. Legal status varies by country, and importation may be restricted. Enforcement practices differ across borders.
Detection of SR9009 in biological samples usually employs liquid chromatography coupled with tandem mass spectrometry. This method can identify the parent compound and sometimes metabolites in urine or blood. Because exposure can be low and clearance may be rapid, sample timing and limits of detection matter. Laboratories validate assays for sensitivity and specificity. Results are interpreted alongside chain-of-custody and quality-control records. Urine is the common matrix for anti-doping analysis, while blood may be used in research settings.
| Property | Value | Notes |
|---|---|---|
| Regulatory status | Not approved for human use | Investigational status in most countries |
| Sports status | Prohibited by WADA | Classified as non-approved or metabolic modulator |
| Common analytical method | LC-MS/MS | Used for trace detection in biological samples |
| Typical test matrices | Urine and blood | Sample choice depends on testing program |
| Human trial data | None published | Effects and safety are not established |
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ, also called NR1D1 and NR1D2. These receptors help regulate circadian rhythms and metabolic gene programs. The compound was developed for laboratory research, not as an approved therapeutic. Its identity is distinct from steroid hormones and selective androgen receptor modulators. Scientific interest centers on how REV-ERB activation changes gene expression in cells and animal models.
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
=== Fructose consumption === Non-alcoholic and alcoholic fatty liver disease share similar histological features, which suggests that they might share common pathogenic pathways. In laboratory research, high fructose levels promote fat accumulation in the liver by stimulating de novo lipogenesis and reducing the beta-oxidation of fat. Unlike the sugar glucose, the enzyme fructokinase rapidly metabolizes fructose. This leads to a decreased level of intracellular adenosine triphosphate (ATP). The decrease in ATP increases oxidative stress and impairments in proper protein synthesis and mitochondrial function in the liver.
In general, thiotepa is a potent inhibitor of CYP2B6, which can lead to increased plasma levels of drugs that are substrates of this enzyme. In addition to this, it may reduce the levels of potentially active metabolites, such as 4-hydroxycyclophosphamide, from cyclophosphamide. Likewise, co-administration with inhibitors of thiotepa's metabolising enzymes can lead to increased thiotepa plasma concentrations. Finally, prolonged apnea has been reported by the administration of thiotepa and is thought to be a result of the inhibition of pseudocholinesterase by thiotepa. For this reason, inhibitors such as succinylcholine and pancuronium should be prevented during thiotepa administration to prevent respiratory failure.
== Bibliography == Clark D (2010). Germs, Genes, & Civilization: how epidemics shaped who we are today. Upper Saddle River, N.J: FT Press. ISBN 978-0-13-701996-0. OCLC 473120711. Crawford D (2007). Deadly Companions: how microbes shaped our history. Oxford New York: Oxford University Press. ISBN 978-0-19-956144-5. OCLC 183198723. Hall B (2008). Strickberger's Evolution: the integration of genes, organisms and populations. Sudbury, Mass: Jones and Bartlett. ISBN 978-0-7637-0066-9. OCLC 85814089. Krasner R (2014). The Microbial Challenge: a public health perspective. Burlington, Mass: Jones & Bartlett Learning. ISBN 978-1-4496-7375-8. OCLC 794228026. Pommerville JC (2014). Fundamentals of Microbiology (10th ed.). Boston: Jones and Bartlett. ISBN 978-1-284-03968-9. Wheelis M (2008). Principles of modern microbiology. Sudbury, Mass: Jones and Bartlett Publishers. ISBN 978-0-7637-1075-0. OCLC 67392796.
Sources: en.wikipedia.org
==== Netherlands ==== In the Netherlands, cider is not as commonly available as in its surrounding countries. In 2007, Heineken started testing a cider-based drink branded Jillz in a number of bars throughout the country. The beverage, an alcopop made by blending sparkling water, fruit flavouring, malt, and cider, is marketed towards female drinkers as an alternative to beer. At the same time, Heineken also introduced Strongbow Gold as a secondary brand to provide the choice of a real cider, which was targeted to a male audience. Both beverages contain 5% alcohol by volume, which is similar to a typical draught beer in the Netherlands. Other brands are available in supermarkets, most noticeably Magners and Savanna Cider, and in liquor stores, generally, a broader range may be obtained.
=== Kinetic exclusion assay === Kinetic exclusion assay (KinExA) measures free (unbound) ligand or free receptor present in a mixture of ligand, receptor, and ligand-receptor complex. The measurements allow quantitation of the active ligand concentration and the binding constants (equilibrium, on and off rates) of the interaction.
=== Targeted sanctions === In jurisdictions not subject to comprehensive sanctions, only transactions related to specific parties are prohibited. Jurisdictions that face targeted sanctions may continue to do business with the United States, with restrictions only placed on specific categories of individuals or entities, and anyone worldwide who materially supports or provides financial, logistical, or technological support for them. According to OFAC, there are approximately 12,000 names on the Specially Designated Nationals and Blocked Persons List (SDN list), which is the most restrictive category of targeted U.S. sanctions, targeting U.S.-designated terrorists, officials and beneficiaries of certain authoritarian regimes, and international criminals such as drug traffickers by blocking their U.S. assets and restricting U.S. persons from engaging in any transactions with them. The following jurisdictions have a specific OFAC sanctions program for SDN designations targeting individuals or entities engaging in sanctionable activities:
== Recent publications == Bale, Sue; V. Jones (2004). Wound Care Nursing, 2nd Edition - A Patient-Centered Approach. Mosby Ltd. ISBN 0-7234-3344-5. Bale, Sue; N. Tebble; V.J. Jones; P.Price (2004). "The benefits of implementing a new skin care protocol in nursing homes". Journal of Tissue Viability. 14 (2): 44–50. PMID 15114926. Bale, Sue; N. Tebble; P. Price (2004). "A topical metronidazole gel used to treat malodorous wounds". British Journal of Nursing. 13 (11): S4–11. PMID 15218439. Jones, V.; S. Bale; K.G. Harding (2004). Acute and chronic wound healing. In "Wound Care Essentials Practice" (S. Baronowski & E.A. Ayello, eds. Lippincott Williams and Wilkins. ISBN 1-58255-274-6.
Sources: en.wikipedia.org
No. It is an investigational compound without approved therapeutic indications. It is sold for research purposes only in many jurisdictions.
Sports authorities prohibit it because it is not approved for human use and has potential performance-enhancing effects. It appears on anti-doping lists under non-approved or metabolic modulator categories.
Detection usually uses liquid chromatography-tandem mass spectrometry. The method targets the parent compound or its metabolites in urine or blood.
Its legal status depends on the country and intended use. It is not an approved medicine in major jurisdictions. In sport, it is prohibited by anti-doping rules.